Aditya Sharma

Prof. Aditya Sharma

University of Virginia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
NKNarendra N. Khanna
Narendra N. Khanna
Mahesh A MaindarkarMahesh A Maindarkar
Mahesh A Maindarkar
VVVijay Viswanathan
Vijay Viswanathan
JFJosé Manuel Mattos Fernandes e Fernandes
José Manuel Mattos Fernandes e Fernandes
SPSudip Paul
Sudip Paul
JSJasjit S. Suri
Jasjit S. Suri
Motivation: The price of medical treatment continues to rise due to (i) an increasing population; (ii) an aging human growth; (iii) disease prevalence; (iv) a rise in the frequency of patients that utilize health care services; and (v) increase in the price. Objective: Artificial Intelligence (AI) is already well-known for its superiority in various healthcare applications, including the segmentation of lesions in images, speech recognition, smartphone personal assistants, navigation, ride-sharing apps, and many more. Our study is based on two hypotheses: (i) AI offers more economic solutions compared to conventional methods; (ii) AI treatment offers stronger economics compared to AI diagnosis. This novel study aims to evaluate AI technology in the context of healthcare costs, namely in the areas of diagnosis and treatment, and then compare it to the traditional or non-AI-based approaches. Methodology: PRISMA was used to select the best 200 studies for AI in healthcare with a primary focus on cost reduction, especially towards diagnosis and treatment. We defined the diagnosis and treatment architectures, investigated their characteristics, and categorized the roles that AI plays in the diagnostic and therapeutic paradigms. We experimented with various combinations of different assumptions by integrating AI and then comparing it against conventional costs. Lastly, we dwell on three powerful future concepts of AI, namely, pruning, bias, explainability, and regulatory approvals of AI systems. Conclusions: The model shows tremendous cost savings using AI tools in diagnosis and treatment. The economics of AI can be improved by incorporating pruning, reduction in AI bias, explainability, and regulatory approvals.

3 January 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
Jasjit SuriJasjit Suri
Jasjit Suri
MBMrinalini Bhagawati
Mrinalini Bhagawati
SPSudip Paul
Sudip Paul
APAthanasios Protogeron
Athanasios Protogeron
PSPetros P. Sfikakis
Petros P. Sfikakis
MKManudeep Kalra
Manudeep Kalra

16 June 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Jasjit SuriJasjit Suri
Jasjit Suri
Sushant AgarwalSushant Agarwal
Sushant Agarwal
GCGian Luca Chabert
Gian Luca Chabert
Alessandro CarrieroAlessandro Carriero
Alessandro Carriero
APAlessio Paschè
Alessio Paschè
MKMannudeep K. Kalra
Mannudeep K. Kalra
Background: The previous COVID-19 lung diagnosis system lacks both scientific validation and the role of explainable artificial intelligence (AI) for understanding lesion localization. This study presents a cloud-based explainable AI, the “COVLIAS 2.0-cXAI” system using four kinds of class activation maps (CAM) models. Methodology: Our cohort consisted of ~6000 CT slices from two sources (Croatia, 80 COVID-19 patients and Italy, 15 control patients). COVLIAS 2.0-cXAI design consisted of three stages: (i) automated lung segmentation using hybrid deep learning ResNet-UNet model by automatic adjustment of Hounsfield units, hyperparameter optimization, and parallel and distributed training, (ii) classification using three kinds of DenseNet (DN) models (DN-121, DN-169, DN-201), and (iii) validation using four kinds of CAM visualization techniques: gradient-weighted class activation mapping (Grad-CAM), Grad-CAM++, score-weighted CAM (Score-CAM), and FasterScore-CAM. The COVLIAS 2.0-cXAI was validated by three trained senior radiologists for its stability and reliability. The Friedman test was also performed on the scores of the three radiologists. Results: The ResNet-UNet segmentation model resulted in dice similarity of 0.96, Jaccard index of 0.93, a correlation coefficient of 0.99, with a figure-of-merit of 95.99%, while the classifier accuracies for the three DN nets (DN-121, DN-169, and DN-201) were 98%, 98%, and 99% with a loss of ~0.003, ~0.0025, and ~0.002 using 50 epochs, respectively. The mean AUC for all three DN models was 0.99 (p < 0.0001). The COVLIAS 2.0-cXAI showed 80% scans for mean alignment index (MAI) between heatmaps and gold standard, a score of four out of five, establishing the system for clinical settings. Conclusions: The COVLIAS 2.0-cXAI successfully showed a cloud-based explainable AI system for lesion localization in lung CT scans.

16 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Jasjit SuriJasjit Suri
Jasjit Suri
MBMrinalini Bhagawati
Mrinalini Bhagawati
SPSudip Paul
Sudip Paul
Athanase D. ProtogerouAthanase D. Protogerou
Athanase D. Protogerou
PSPetros P. Sfikakis
Petros P. Sfikakis
Luca SabaLuca Saba
Luca Saba
Background and Motivation: Cardiovascular disease (CVD) causes the highest mortality globally. With escalating healthcare costs, early non-invasive CVD risk assessment is vital. Conventional methods have shown poor performance compared to more recent and fast-evolving Artificial Intelligence (AI) methods. The proposed study reviews the three most recent paradigms for CVD risk assessment, namely multiclass, multi-label, and ensemble-based methods in (i) office-based and (ii) stress-test laboratories. Methods: A total of 265 CVD-based studies were selected using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) model. Due to its popularity and recent development, the study analyzed the above three paradigms using machine learning (ML) frameworks. We review comprehensively these three methods using attributes, such as architecture, applications, pro-and-cons, scientific validation, clinical evaluation, and AI risk-of-bias (RoB) in the CVD framework. These ML techniques were then extended under mobile and cloud-based infrastructure. Findings: Most popular biomarkers used were office-based, laboratory-based, image-based phenotypes, and medication usage. Surrogate carotid scanning for coronary artery risk prediction had shown promising results. Ground truth (GT) selection for AI-based training along with scientific and clinical validation is very important for CVD stratification to avoid RoB. It was observed that the most popular classification paradigm is multiclass followed by the ensemble, and multi-label. The use of deep learning techniques in CVD risk stratification is in a very early stage of development. Mobile and cloud-based AI technologies are more likely to be the future. Conclusions: AI-based methods for CVD risk assessment are most promising and successful. Choice of GT is most vital in AI-based models to prevent the RoB. The amalgamation of image-based strategies with conventional risk factors provides the highest stability when using the three CVD paradigms in non-cloud and cloud-based frameworks.

9 September 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
AJAmer M. Johri
Amer M. Johri
KSKrishna V. Singh
Krishna V. Singh
LMLaura E. Mantella
Laura E. Mantella
LSLuca Saba
Luca Saba
ASAditya Sharma
Aditya Sharma
Jasjit SuriJasjit Suri
Jasjit Suri

28 August 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
Ankush D JamthikarAnkush D Jamthikar
Ankush D Jamthikar
DGDeep Gupta
Deep Gupta
APAnudeep Puvvula
Anudeep Puvvula
AJAmer M Johri
Amer M Johri
NKNarendra N. Khanna
Narendra N. Khanna
Jasjit SuriJasjit Suri
Jasjit Suri